| 23.04 07:00 | dpa-AFX: Vertex Pharma Obtains Exclusive License To TreeFrog's Cell Manufacturing Technology, C-Stem |
| 23.04 06:53 | dpa-AFX: *VERTEX PHARMA OBTAINS EXCLUSIVE LICENSE TO TREEFROG'S PROPRIETARY CELL MANUFACTURING TECHNOLOGY, C-STEM |
| 11.04 22:16 | MÄRKTE USA/Wall Street auf Erholungskurs - Nasdaq sehr fest |
| 11.04 18:45 | MÄRKTE USA/Wall Street nach Vortagestalfahrt uneinheitlich |
| 11.04 15:41 | MÄRKTE USA/Börsen starten nach Vortagesminus gut behauptet |
| 11.04 15:37 | dpa-AFX: *ALPINE IMMUNE SCIENCES +36% - VERTEX PHARMA (+0,9%) WILL ÜBERNEHMEN |
| 11.04 15:04 | MÄRKTE USA/Börsen nach Vortagesminus wenig verändert erwartet |
| 11.04 14:50 | dpa-AFX: *ALPINE IMMUNE SCIENCES VORBÖRSLICH +36,6% - VERTEX PHARMA WILL ÜBERNEHMEN |
| 11.04 12:27 | MARKT USA/Wall Street etwas leichter erwartet |
| 10.04 22:46 | dpa-AFX: Vertex Pharmaceuticals To Buy Alpine Immune Sciences For $4.9 Bln |
| 10.04 22:05 | dpa-AFX: *VERTEX ENTERS INTO AGREEMENT TO ACQUIRE ALPINE IMMUNE SCIENCES |
| 01.04 17:49 | dpa-AFX: Vertex's NDS For Exagamglogene Autotemcel Gets Health Canada's Priority Review Acceptance |
| 01.04 17:05 | dpa-AFX: *VERTEX ANNOUNCES NEW DRUG SUBMISSION FOR EXAGAMGLOGENE AUTOTEMCEL ACCEPTED FOR PRIORITY REVIEW BY HEALTH CANADA |
| 01.04 14:55 | dpa-AFX: Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease |
| 01.04 14:15 | dpa-AFX: *VERTEX ADVANCES INAXAPLIN INTO PHASE 3 PORTION OF PHASE 2/3 TRIAL FOR TREATMENT OF APOL1-MEDIATED KIDNEY DISEASE |
| 21.03 13:45 | dpa-AFX: Vertex Gets FDA Nod Of IND For VX-407 For Autosomal Dominant Polycystic Kidney Disease |
| 21.03 13:08 | dpa-AFX: *VERTEX ANNOUNCES FDA CLEARANCE OF IND FOR VX-407 FOR TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE |
| 23.02 14:56 | dpa-AFX: Vertex's Kalydeco Gets CHMP Positive Opinion For Label Expansion To Cystic Fibrosis In Infants |
| 23.02 13:52 | dpa-AFX: *VERTEX'S KALYDECO RECEIVES CHMP POSITIVE OPINION FOR TREATMENT OF INFANTS WITH CYSTIC FIBROSIS |
| 13.02 08:26 | dpa-AFX: Vertex : EU Okays Casgevy For Sickle Cell Disease & Transfusion-Dependent Beta Thalassemia Treatment |
|
|
